Unicycive Therapeutics Inc
UNCY
NASDAQ
Biotechnology
$5.51
USD
+0.11 (+2.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $137.24M
Volume 767.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-35.22M
TTM
-11.8%
YoY
Operating Cash Flow
$-27.84M
TTM
+16.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.2 | 4.4 | 5.0 | 6.8 | 7.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 7.0 | 7.3 | 7.2 | 8.4 | 10.1 |
Operating Income | -7.0 | -7.3 | -7.2 | -8.4 | -10.1 |
EBITDA | -7.0 | -7.3 | -7.2 | -8.4 | -10.1 |
Other Income / Expense | 0.4 | 1.1 | -7.8 | -4.8 | 8.0 |
Total Other Income / Expense | 0.5 | 1.3 | -7.4 | -4.4 | 8.4 |
Income Before Income Taxes | -6.4 | -6.0 | -14.7 | -12.8 | -1.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.4 | -6.0 | -14.7 | -12.8 | -1.7 |
Consolidated Net Income / Loss | -6.4 | -6.0 | -14.7 | -12.8 | -1.7 |
Net Income Attributable to Common Shareholders | -6.4 | -6.0 | -14.7 | -12.8 | -1.7 |
Basic EPS | -$0.52 | -$0.33 | -$0.68 | -$0.54 | -$0.06 |
Diluted EPS | -$0.52 | -$0.33 | -$0.71 | -$0.54 | -$0.06 |
Basic Shares Outstanding | 12.3M | 18.1M | 21.5M | 23.9M | 26.9M |
Diluted Shares Outstanding | 12.3M | 18.1M | 20.8M | 23.9M | 26.9M |